New quadruple therapy aims to crush High-Risk myeloma
NCT ID NCT07334535
First seen Jan 12, 2026 · Last updated May 22, 2026 · Updated 23 times
Summary
This study compares a four-drug combination (Isa-VRD) against the standard three-drug regimen (VRD) for people newly diagnosed with high-risk multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if adding isatuximab helps achieve deeper cancer remission (MRD negativity) at 12 months. About 117 participants will be randomly assigned to one of the two treatment groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Junling Zhuang
Beijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.